Nocturia in Parkinson’s disease

Close metadata

OBJECTIVE

Evaluation of nocturia and its relationship with clinical characteristics of Parkinson’s disease (PD) and dopaminergic therapy.

MATERIAL AND METHODS

One hundred and thirteen patients with PD of I-III Hoehn and Yahr stage (H&Y) were examined using the following scales: IPSS, including nocturia domain, UPDRS, Sch&En, PDQ-39, MMSE, FAB, BDI, STAI-S and STAI-T, PFS-16, NMSQuest, GDSS, GSRS, and orthotest.

RESULTS

Nocturia was detected in 93 patients. It depended on the age of the patients (rS=0.345; p<0.001) and was more spread among women (p=0.002). We obtained positive correlations of nocturia (p<0.05) with: PDQ-39 (rS=0.296), H&Y (rS=0.223), UPDRS (rS=0.265) and its items (speech, walking disorders, standing up from chair, posture and postural stability), NMSQ (rS=0.318), FAB (rS= –0.359), BDI, STAI-S and STAI-T, PFS-16, gastrointestinal parameters and blood pressure in the supine position. No significant effect of dopaminergic therapy on the severity of nocturia was found. According to regression analysis (stepwise method), predictors of nocturia are depression, higher lying blood pressure, constipation and postural instability (R2=0.474).

CONCLUSIONS

Nocturia is the most common urological symptom in patients with PD and it significantly reduces the quality of life starting from the early stages of the disease. Nocturia increases as PD progresses, it is independent of dopaminergic medications, and it is directly associated with a number of parkinsonian symptoms (postural, frontal cognitive, affective and autonomic), which are partly dopamine-resistant. This indicates the common pathogenesis of nocturia and other symptoms of PD and the significant influence of polytransmitter imbalance.

Keywords:

Parkinson’s disease

non-motor disorders

autonomic disorders

urological dysfunction

nocturia

Authors:

Pilipovich A.A.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-7416-9050

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

SPIN RSCI: 5084-1379
ORCID: 0000-0003-3259-3691

Makarov S.A.

Center for Surgical Treatment of Obesity and Metabolic Disorders — St. George Hospital

ORCID: 0000-0002-8423-8002

Received:

20.12.2023

Accepted:

23.12.2023

List of references:

Batla A, Phé V, De Min L, et al. Nocturia in Parkinson’s Disease: Why Does It Occur and How to Manage? Mov Disord Clin Pract. 2016;3(5):443-451. https://doi.org/10.1002/mdc3.12374
Deane KH, Flaherty H, Daley DJ, et al. Priority setting partnership to identify the top 10 research priorities for the management of Parkinson’s disease. BMJ Open. 2014;4(12):e006434. https://doi.org/10.1136/bmjopen-2014-006434
Diaconu Ş, Irincu L, Ungureanu L, et al. Nocturia and Sleep in Parkinson’s Disease. J Pers Med. 2023;13(7):1053. https://doi.org/10.3390/jpm13071053
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399-406. https://doi.org/10.1002/mds.23462
Vaughan CP, Juncos JL, Trotti LM, et al. Nocturia and overnight polysomnography in Parkinson disease. Neurourol Urodyn. 2013;32(8):1080-1085. https://doi.org/10.1002/nau.22365
Balash Y, Peretz C, Leibovich G, et al. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol. 2005;252(11):1310-1315. https://doi.org/10.1007/s00415-005-0855-3
Asplund R. Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriatr. 2006;43(3):319-326. https://doi.org/10.1016/j.archger.2005.12.002
Benli E, Özer FF, Kaya Y, et al. Is there a difference between Parkinson disease patients and a control group in terms of urinary symptoms and quality of life? Turk J Med Sci. 2016;46(6):1665-1671. https://doi.org/10.3906/sag-1507-148
Barone P, Antonini A, Colosimo C, et al. PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641-1649. https://doi.org/10.1002/mds.22643
Winge K, Skau AM, Stimpel H, et al. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25(2):116-122. https://doi.org/10.1002/nau.20193
Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22(11):1623-1629. https://doi.org/10.1002/mds.21586
Van Kerrebroeck P, Abrams P, Chaikin D, et al. International Continence Society. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90(suppl 3):11-15. https://doi.org/10.1046/j.1464-410x.90.s3.3.x
Smith M, Seth J, Batla A, et al. Nocturia in Patients With Parkinson’s Disease. Mov Disord Clin Pract. 2015;3(2):168-172. https://doi.org/10.1002/mdc3.12279
Aziz NA, Pijl H, Frölich M, et al. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson’s disease. J Neuroendocrinol. 2011;23(6):519-524. https://doi.org/10.1111/j.1365-2826.2011.02134.x
Batla A, Simeoni S, Uchiyama T, et al. Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson’s disease. Eur J Neurol. 2021;28(6):1884-1892. https://doi.org/10.1111/ene.14774
Pfeiffer R, Bodis-Wollner I. Parkinson’s Disease and Nonmotor Dysfunction. Humana Press Inc. 2005;308.
Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson’s disease. Int J Urol. 2014;21:638-646. https://doi.org/10.1111/iju.12421
Winge K, Friberg L, Werdelin L, et al. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12:842-850. https://doi.org/10.1111/j.1468-1331.2005.01087.x
Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci. 2001;187:55-59. https://doi.org/10.1016/S0022-510X(01)00521-4
Martinez-Ramirez D, Velazquez-Avila ES, Almaraz-Espinoza A, et al. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease. Park Dis. 2020;2020:1694547. https://doi.org/10.1155/2020/1694547
Romain J, Torny F, Dumas JP, et al. La polyurie nocturne est-elle plus fréquente chez les patients parkinsoniens? [Is nocturnal polyuria more frequent among patients with Parkinson’s disease?]. Prog Urol. 2015;25(6):312-317. https://doi.org/10.1016/j.purol.2015.02.004
Campos-Sousa RN, Quagliato E, da Silva BB, et al. Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr. 2003;61(2B):359-363. https://doi.org/10.1590/s0004-282x2003000300007
Saraf U, Batla A, Sakakibara R, et al. The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease. Drugs Aging. 2023;40(10):909-917. https://doi.org/10.1007/s40266-023-01060-2
Brusa L, Petta F, Pisani A, et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68(18):1455-1459. https://doi.org/10.1212/01.wnl.0000260605.12506.86
Bolezni predstatel’noi zhelezy. Pod red. Alyaeva Yu.G. M.: GEOTAR-Media; 2009. (In Russ.). https://medknigaservis.ru/wp-content/uploads/2019/01/Q0008940.pdf
Lemack GE, Dewey RB Jr, Roehrborn CG, et al. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson’s disease. Urology. 2000;56(2):250-254. https://doi.org/10.1016/s0090-4295(00)00641-5
Sammour ZM, Gomes CM, Barbosa ER, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28(6):510-515. https://doi.org/10.1002/nau.20681
Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci. 2001;92(1-2):76-85. https://doi.org/10.1016/S1566-0702(01)00295-8
Kuno S, Mizuta E, Yamasaki S, et al. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004;10(3):181-187. https://doi.org/10.1016/j.parkreldis.2003.08.001
Xu D, Han S, Wang J, et al. Relationship between Lower Urinary Tract Dysfunction and Clinical Features in Chinese Parkinson’s Disease Patients. Parkinsons Dis. 2019;2019:6820937. https://doi.org/10.1155/2019/6820937
Sakakibara R, Panicker J, Finazzi-Agro E, et al. Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551-563. https://doi.org/10.1002/nau.22764
Berganzo K, Díez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol. 2013;260(7):1752-1756. https://doi.org/10.1007/s00415-013-6859-5
Rana AQ, Paul DA, Qureshi AM, et al. Association between nocturia and anxiety in Parkinson’s disease. Neurol Res. 2015;37(7):563-567. https://doi.org/10.1179/1743132815Y.0000000010

Close metadata